BayMedica’s VP of Commercial Operations, Chris Meiering, joins Shadd Dales of The Dales Report to talk about the growth opportunities in the cannabinoid industry.
In the interview, Chris talks about how the cannabinoids industry is maturing and the big changes he expects to see in the market. With the saturation of CBD products, Chris talks about the opportunities of rare cannabinoids as a differentiator and being able to offer something unique. He talks about how modern manufacturing methods make these minor cannabinoids, which were too difficult to get from plant extraction, are now cost effective for the consumer health and wellness industry.
Chris talks about the importance of a regulatory framework for the industry to ensure no medical claims are made without proven therapeutic benefit through clinical trials. He also talks InMed and BayMedica’s cannabinoid pharmaceutical, manufacturing and commercial programs, making them well-positioned for the cannabinoid industry’s growth.